Fairvalue-Calculator Fairvalue-Calculator
EN DE

Avenue Therapeutics, Inc (ATXI) Fair Value & Analysis

Healthcare · US · Market cap $890K

Price$0.3500
Fair Value$0.5300
Upside+51.4%
Quality95/100
Evidence: Low Range $0.3500 – $0.6700

Fair value as of: Jun 25, 2026

Analysis

Avenue Therapeutics, Inc (ATXI) currently trades at $0.3500, while our model-based Fair Value estimate is $0.5300 — implying the stock looks roughly 51.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Avenue Therapeutics, Inc (ATXI) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.5300 versus a price of $0.3500 — about +51% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ATXI?
Our 21-model fair value for Avenue Therapeutics, Inc is $0.5300 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.3500.
What is the quality score of ATXI?
Avenue Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.